AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults
📅 AbbVie announced on June 2, 2026, that the European Commission has approved AQUIPTA® (atogepant) for the acute treatment of migraine in adults.
💊 The approval covers both adults with and without aura, allowing the medication to be taken as needed (PRN).
🔄 This marks the second indication for AQUIPTA in the EU, following its existing approval for once-daily preventive treatment in patients with at least four migraine days per month.
📊 Approval is based on data from the pivotal Phase 3 ECLIPSE trial, which demonstrated statistically significant pain freedom at two hours versus placebo during the first migraine attack.
⏱️ Clinical data showed sustained pain freedom lasting from 2 to 48 hours after treatment of a single migraine attack.
📈 The study met its primary endpoint with p<0.0001, showing superiority over placebo in achieving pain freedom at two hours post-treatment for the first attack.
🎯 Secondary endpoints included freedom from the most bothersome symptom, pain relief, reduced rescue medication use within 24 hours, and consistent effects across multiple attacks.
👥 The ECLIPSE study enrolled 1,328 adults aged 18 to 75 years across 149 sites in Europe, the UK, Japan, China, South Korea, and Taiwan.
⚠️ During the 16-week double-blind period, the most common adverse events were nasopharyngitis and upper respiratory tract infection, consistent with the preventive treatment profile.
🤢 Nausea was reported as the most common adverse drug reaction during acute treatment studies (9%), followed by constipation (8%) and fatigue/somnolence (5%).
⚠️ AQUIPTA is contraindicated in patients with hypersensitivity to atogepant or any excipients and is not recommended for patients with severe hepatic impairment.
🤰 The drug is not recommended during pregnancy or for women of childbearing potential not using contraception, though minimal transfer into breast milk was observed.
🚗 Patients should exercise caution when driving or using machinery as the drug may cause somnolence in some individuals.
🌍 Migraine affects roughly 14% of the global population and is a leading cause of years lived with disability, particularly among women aged 25 to 55.
💰 In six European countries, migraine contributes an estimated economic burden of €35 billion to €557 billion in lost productivity from paid and unpaid work.
🏢 AbbVie's executive vice president Roopal Thakkar stated that this approval addresses unmet needs for acute treatment options in Europe.
👨⚕️ Uwe Reuter, president of the European Headache Federation, noted that effective treatment can help clinicians better address the socioeconomic burden of migraine.
🌐 AQUIPTA is marketed as QULIPTA® in the U.S., Canada, Israel, and Puerto Rico, while retaining the name AQUIPTA in the EU.
🔬 The ECLIPSE trial was a 24-week, multicenter, randomized, double-blind, placebo-controlled multiple-attack study with an open-label extension.
📄 More information on the ECLIPSE trial can be found at www.clinicaltrials.gov under identifier NCT06241313.
⚖️ AbbVie cautioned that forward-looking statements in the release are subject to risks including competition, intellectual property challenges, and global macroeconomic factors.
- AbbVie received European Commission approval for AQUIPTA® (atogepant) as the second indication in the EU, expanding its migraine therapy portfolio to include both acute treatment and once-daily prophylaxis.
- The pivotal Phase 3 ECLIPSE trial demonstrated that AQUIPTA achieved statistically significant pain freedom at two hours versus placebo during the first migraine attack (p<0.0001).
- Clinical data showed sustained pain freedom from 2 to 48 hours, providing fast and lasting relief for patients with acute migraine attacks.
- The drug demonstrated a clinically meaningful and consistent effect across multiple migraine attacks, addressing unmet needs in the European market.
- AQUIPTA met its primary endpoint of superior efficacy versus placebo in achieving pain freedom at two hours after treatment of the first migraine attack.
- The study showed statistical significance versus placebo for secondary endpoints including reduced use of rescue medication within 24 hours and absence of the most bothersome symptom.
- Safety data from the 16-week treatment period indicated that AQUIPTA's safety profile was consistent with its approved preventive indication, with common adverse events limited to nasopharyngitis and upper respiratory tract infection.
- The approval is limited to the European Union, leaving other markets such as the US (where it is marketed as QULIPTA) and others potentially subject to different regulatory timelines or outcomes.
- Nausea remains a significant adverse event, occurring in 9% of patients overall and being the most common reason for discontinuation (0.4%), which could impact patient adherence and real-world uptake.
- The drug is contraindicated in patients with hypersensitivity to atogepant or excipients and not recommended for those with severe hepatic impairment, limiting its use in specific patient populations.
- AQUIPTA is not recommended during pregnancy and for women of childbearing potential not using contraception, which may restrict access for a segment of the migraine population.
- While somnolence has negligible influence on driving ability overall, it may still cause drowsiness in some patients, requiring caution before operating machinery or driving.
- The forward-looking statements explicitly warn that actual results may differ materially due to risks including challenges to intellectual property and competition from other products.
